BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-89@catalystbrief.girapphe.com
DTSTAMP:20261117T061557Z
LAST-MODIFIED:20261117T061557Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Vertex Pharmaceuticals Incorporated — Suzetrigine [Jan 2
 027]
DESCRIPTION:Phase 3 primary completion: Evaluation of the Long-term Safety 
 and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabet
 ic Peripheral Neuropathy (DPN).\nSource: https://clinicaltrials.gov/study/
 NCT06696443\nhttps://catalystbrief.girapphe.com/e/89?lang=en\nNot investme
 nt advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/89?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
